Showing results (1-10 of 53) with videos related to
Sort By:
Pageof 6
Clinical Breast Cancer|July 17, 2003
Mammalian target of rapamycin: a new molecular target for breast cancerMonica M Mita, Alain Mita, Eric K RowinskyCancer Biology & Therapy|September 26, 2003
The molecular target of rapamycin (mTOR) as a therapeutic target against cancerMonica M Mita, Alain Mita, Eric K RowinskyCurrent Drug Targets|July 23, 2011
Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinicMatthew A Spear, Patricia LoRusso, Alain Mita, et al.Targeted Oncology|May 3, 2011
The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomasSushma Vemulapalli, Alain Mita, Yesid Alvarado, et al.Targeted Oncology|June 28, 2017
Targeting the Wnt Pathway in Cancer: A Review of Novel TherapeuticsRoya Tabatabai, Yuliya Linhares, David Bolos, et al.Cancer Treatment and Research|February 14, 2018
Perspectives in Head and Neck Medical OncologyIdoroenyi Amanam, Rohan Gupta, Alain Mita, et al.Expert Opinion on Investigational Drugs|November 18, 2008
Deforolimus (AP23573) a novel mTOR inhibitor in clinical developmentMonica Mita, Kamalesh Sankhala, Issam Abdel-Karim, et al.Targeted Oncology|April 22, 2009
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agentsKamalesh Sankhala, Alain Mita, Kevin Kelly, et al.Future Oncology (London, England)|April 21, 2009
Targeting the mTOR pathway using deforolimus in cancer therapyDevalingam Mahalingam, Kamalesh Sankhala, Alain Mita, et al.Expert Opinion on Biological Therapy|June 17, 2009
Reovirus-based therapy for cancerKevin Kelly, Steffan Nawrocki, Alain Mita, et al.Pageof 6